title: [Autoimmune blistering diseases].
abstract: Autoimmune blistering diseases are characterized by the production of pathogenic autoantibodies that are responsible for the formation of epidermal blisters. Major advances in the understanding of the pathogenesis of these disorders have allowed the development of new therapeutic agents. Recent epidemiologic data showed that bullous pemphigoid mainly affects elderly patients. Bullous pemphigoid is often associated with degenerative neurologic disorders. A major increase in the incidence of bullous pemphigoid has been observed in France. Treatment of bullous pemphigoid is mainly based on superpotent topical corticosteroids. The role of desmosomal proteins has been demonstrated in the initiation, propagation and persistence of the autoimmune response in pemphigus. Several studies have shown a correlation between anti-desmoglein antibody titers and disease activity. Pemphigus susceptibility genes have been identified. Oral corticosteroids remain the mainstay of pemphigus treatment. Dramatic and long-lasting improvement has been recently obtained with rituximab in recalcitrant types of pemphigus. Other autoimmune junctional blistering diseases are rare entities, whose prognosis can be severe. Their diagnosis has been improved by the use of new immunological assays and immunoelectronic microscopy. Immunosupressants are widely used in severe types in order to prevent mucosal sequelae.
authors.affiliation: Clinique dermatologique, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France. Electronic address: sophie.duvert-lehembre@chu-rouen.fr.
authors.forename: S
authors.initials: S
authors.lastname: Duvert-Lehembre
authors.affiliation: Clinique dermatologique, CHU de Rouen, 1, rue de Germont, 76031 Rouen cedex, France.
authors.forename: P
authors.initials: P
authors.lastname: Joly
mesh_terms: D001323:Autoantibodies / Q000009:adverse effects; D001327:Autoimmune Diseases / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D001768:Blister / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology* / Q000628:therapy; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D010391:Pemphigoid, Bullous / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology / Q000628:therapy; D010392:Pemphigus / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy
chemical_list: D001323:Autoantibodies
keywords: Autoimmune blistering diseases; Bullous pemphigoid; Maladies bulleuses auto-immunes; Mucous membrane pemphigoid; Pemphigoïde bulleuse; Pemphigoïde des muqueuses; Pemphigus; Traitement; Treatment